CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited (CNTB) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.4% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.
Sector
Healthcare
Industry
Biotechnology